Louise Chen

if you could provide more color on your opportunities for an extended half-life IL-23 and also your oral peptide IL-23

Do you want to be the number three player behind Novo and Lilly, or are you assuming a higher position than that with your product?

I wanted to ask you about TEPEZZA and your thoughts on another potential competitor coming to market and then also where you stand with AMG seven thirty two for TED.

which of those additional indications are you most excited by?

how do you see these all coming together to give Bristol a more comprehensive hold on the market?

what type of share gains you expect for Anidocel in the fourth-line setting if you're approved, especially in light of competition from entrenched players

I'm wondering what you think the Street may be missing about the competitiveness of your product

which key products do you think will drive the reacceleration of your growth in 2029 and beyond?

It's been a couple of years since you completed the acquisition of Seagen, and I'm just curious how that integration has gone and then how has that deal really increased your leadership in oncology